Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01604408 · ClinicalTrials.gov registry record · Phase 2

A Study in Older Participants Who Have Fallen and Have Muscle Weakness

A Phase 2 study, sponsored by Eli Lilly and Company.

Completed
Registry status
Phase 2
Development phase
201
Enrollment target

NCT01604408: Completed Phase 2 study, sponsored by Eli Lilly and Company.

NCT01604408 is a Phase 2 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 201 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% higher). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01604408, a Phase 2 study, has completed, sponsored by Eli Lilly and Company.

COMPLETED
Registry status
Phase 2
Development phase
201 participants
Enrollment target

Study Summary

LY2495655 is an investigational drug being tested for muscle wasting.

Primary Outcome

Change from baseline to 24-week endpoint in aLBM, as measured by dual energy x-ray absorptiometry (DEXA), is presented. Least squares (LS) means were calculated using a mixed model repeated measures (MMRM) with treatment, visit, and treatment-by-visit interaction as fixed effects and baseline aLBM as covariate.

Interventions

  • DRUG Placebo
  • BIOLOGICAL LY2495655

Trial Details

FieldValue
Enrollment Target 201 participants
Start Date 2012-05
Est. Completion 2013-12
Phase Phase 2
Eli Lilly and Company

1,341 total trials

What the finished NCT01604408 record still lists

NCT01604408 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (51% higher).

The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.

NCT01604408 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01604408 about?

NCT01604408 is a clinical study titled "A Study in Older Participants Who Have Fallen and Have Muscle Weakness". LY2495655 is an investigational drug being tested for muscle wasting.

What is the current status of trial NCT01604408?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 201 participants. The study started on 2012-05. Estimated completion is 2013-12.

What interventions are being tested in trial NCT01604408?

The interventions under investigation include: Placebo (DRUG), LY2495655 (BIOLOGICAL).

Who is sponsoring clinical trial NCT01604408?

This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01604408's enrollment target sits among peer trials

201 302nd of 2000 higher than 1,697 of 2,000 other Phase 2 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT04422652 · 201 participants · Phase 2

    Combination of Novel Therapies for CKD Comorbid Depression

  • NCT05327114 · 201 participants · Phase 2

    Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

  • NCT06099769 · 201 participants · Phase 2

    A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer

  • NCT06274528 · 201 participants · Phase 2

    DORA and LP in Alzheimer's Disease Biomarkers

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01604408, the US trial registry maintained by the National Library of Medicine. NCT01604408 (mid enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.